Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moleculin Biotech ( (MBRX) ) has provided an update.
Moleculin Biotech, Inc. is set to host an engaging Virtual Acute Myeloid Leukemia KOL event on October 14, 2024, which will feature discussions with top medical experts on the potential of Annamycin to revolutionize AML treatment. The company also highlights their pivotal Phase 3 MIRACLE trial aimed at accelerated approval of Annamycin in combination with cytarabine for patients with relapsed or refractory AML. Investors and interested parties can join the event via webcast to gain insights into Moleculin’s advanced pipeline targeting challenging tumors and viruses.
See more insights into MBRX stock on TipRanks’ Stock Analysis page.